Adiponectin through its biphasic serum level is a useful biomarker during transition from diastolic dysfunction to systolic dysfunction - an experimental study

Lipids in Health and Disease

Junbo Ge³  Yunzeng Zou³  Michael Fu²  Chunlin Zhong¹  Hongmin Zhu¹  Xuejuan Jin¹  Juying Qian¹  Jingmin Zhou¹  Mingqiang Fu¹ 

[1]Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China

[2]Department of Medicine, Sahlgrenska University Hospital/Sahlgrenska, Gothenburg, Sweden

[3]Institutes of Biomedical Sciences, Fudan University, Shanghai, China

关键词: Biomarker;    Adiponectin;    Systolic function;    Diastolic function;    Hypertension;   

Others  :  1160224
DOI  :  10.1186/1476-511X-11-106

 received in 2012-05-15, accepted in 2012-08-12,  发布年份 2012

【 摘 要 】

Background

Adiponectin is reported to relate with cardiovascular diseases, we sought to examine whether adiponectin is associated with disease progression of heart failure from hypertension in rats in comparison with other known biomarkers and echocardiographic parameters. Spontaneously hypertensive rats (SHR, n = 35), aged 1 month, were used and followed up to 18 months. High frequency echocardiography was performed both at baseline and every 3 months thereafter. Moreover, serum levels of N-terminal pro-natriuretic peptide (NT-proBNP) and interleukin-6 (IL-6) as well as serum level and tissue expression of adiponectin were determined at the same time as echocardiography.

Results

The results clearly demonstrated time-dependent progression of hypertension and heart dysfunction as evidenced by gradually increased left ventricular mass index, NT-proBNP, IL-6 as well as gradually decreased cardiac function as assessed by echocardiography. Meanwhile, tissue and serum adiponectin decreased from 3 months and reached plateau until 12 months in parallel with decreasing of cardiac diastolic function. Thereafter, adiponectin levels increased prior to occurrence of systolic dysfunction. Adiponectin concentration is inversely related withNT-proBNP, IL-6 and E/E′ (correlation coefficient (r) = −0.756 for NT-proBNP, p < 0.001, -0.635 for IL-6, p = 0.002, and −0.626 for E/E′, p = 0.002, respectively) while positively correlated with E/A and E′/A′ (r = 0.683 for E/A, p = 0.001, 0.671 for E′/A′, p = 0.001, respectively). No difference for adiponectin distribution among visceral adipose tissues was found.

Conclusion

Adiponectin through its biphasic serum level is a useful biomarker during transition from diastolic dysfunction to systolic dysfunction.

【 授权许可】

   
2012 Zhou et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Ikeoka D, Mader JK, Pieber TR: Adipose tissue, inflammation and cardiovascular disease. Rev Assoc Med Bras 2010, 56:116-121.
• [2]Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
• [3]Calabro P, Yeh ET: Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. Subcell Biochem 2007, 42:63-91.
• [4]Scherer PE: Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006, 55:1537-1545.
• [5]Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
• [6]Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
• [7]Mao X, Hong JY, Dong LQ: The adiponectin signaling pathway as a novel pharmacological target. Mini Rev Med Chem 2006, 6:1331-1340.
• [8]Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K: Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004, 10:1384-1389.
• [9]Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
• [10]Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-451.
• [11]Szmitko PE, Teoh H, Stewart DJ, Verma S: Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol 2007, 292:H1655-H1663.
• [12]Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K, Adachi M: Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 2006, 55:478-488.
• [13]Imatoh T, Miyazaki M, Momose Y, Tanihara S, Une H: Adiponectin levels associated with the development of hypertension: a prospective study. Hypertens Res 2008, 31:229-233.
• [14]Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED, Lam TH, Lam KS: Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007, 49:1455-1461.
• [15]Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978, 58:1072-1083.
• [16]Maron BJ, Spirito P, Green KJ, Wesley YE, Bonow RO, Arce J: Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1987, 10:733-742.
• [17]Trippodo NC, Frohlich ED: Similarities of genetic (spontaneous) hypertension. Man and rat. Circ Res 1981, 48:309-319.
• [18]Boluyt MO, Bing OH, Lakatta EG: The ageing spontaneously hypertensive rat as a model of the transition from stable compensated hypertrophy to heart failure. Eur Heart J 1995, 16:19-30.
• [19]de Simone G, Wallerson DC, Volpe M, Devereux RB: Echocardiographic measurement of left ventricular mass and volume in normotensive and hypertensive rats. Necropsy validation. Am J Hypertens 1990, 3:688-696.
• [20]Tanaka N, Dalton N, Mao L, Rockman HA, Peterson KL, Gottshall KR, Hunter JJ, Chien KR, Ross J Jr: Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation 1996, 94:1109-1117.
• [21]Schaefer A, Meyer GP, Brand B, Hilfiker-Kleiner D, Drexler H, Klein G: Effects of anesthesia on diastolic function in mice assessed by echocardiography. Echocardiography 2005, 22:665-670.
• [22]Brutsaert DL: Diagnosing primary diastolic heart failure. Eur Heart J 2000, 21:94-96.
• [23]Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y, Mano T, Akehi N, Hori M, Lim YJ, Mishima M, Masuyama T: Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004, 43:55-60.
• [24]Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Knudsen CW, Perez A, Kamin R, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study Investigators: Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003, 41:2010-2017.
• [25]Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead A, Yandle TG, Richards AM, Starling RC, Young JB, Thomas JD, Klein AL: Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 2004, 43:416-422.
• [26]Mottram PM, Leano R, Marwick TH: Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol 2003, 92:1434-1438.
• [27]Alehagen U, Lindstedt G, Levin LA, Dahlström U: The risk of cardiovascular death in elderly patients with possible heart failure. Results from a 6-year follow-up of a Swedish primary care population. Int J Cardiol 2005, 100:17-27.
• [28]Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM: Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 2004, 13:236-242.
• [29]George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, Grossman E, Sheps D, Keren G, Roth A: Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006, 92:1420-1424.
• [30]Oztürk M, Dursunoğlu D, Göksoy H, Rota S, Gür S: Evaluation of serum adiponectin levels in patients with heart failure and relationship with functional capacity. Turk Kardiyol Dern Ars 2009, 37:384-390.
• [31]Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746-26749.
• [32]Staiger H, Tschritter O, Machann J, Thamer C, Fritsche A, Maerker E, Schick F, Häring HU, Stumvoll M: Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 2003, 11:368-372.
• [33]Fisher FM, McTernan PG, Valsamakis G, Chetty R, Harte AL, Anwar AJ, Starcynski J, Crocker J, Barnett AH, McTernan CL, Kumar S: Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm Metab Res 2002, 34:650-654.
• [34]Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002, 13:134-141.
• [35]Tietge UJ, Böker KH, Manns MP, Bahr MJ: Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004, 287:E82-E89.
• [36]Arner P: Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab 2005, 19:471-482.
• [37]Nishida M, Funahashi T, Shimomura I: Pathophysiological significance of adiponectin. Med Mol Morphol 2007, 40:55-67.
• [38]Skurk T, Alberti-Huber C, Herder C, Hauner H: Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007, 92:1023-1033.